Kiadis Pharma expands presence in the United States

Kiadis Pharma expands presence in the United States

Scott Holmes commences position as chief financial officer
Amy Sullivan appointed senior vice president, corporate affairs
Both are based in Boston, Massachusetts

Amsterdam, The Netherlands, and Boston, Massachusetts, USA – January 4, 2019 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that it has expanded its presence in the United States. Two of Kiadis’ key interfaces for the financial markets are now based in Boston, with the previously announced appointment of Scott Holmes as chief financial officer and today’s announcement of Amy Sullivan as senior vice president of corporate affairs, both effective January 1, 2019. Ms. Sullivan will replace Karl Hård, who resigned effective December 31st to pursue other interests.

Arthur Lahr, CEO of Kiadis Pharma, commented: “I would like start by thanking Karl for his service to Kiadis and wishing him well in all his future endeavors.  I am excited to officially welcome both Scott and Amy to our company. They are a strong team and together bring a wealth of capital markets experience and strong relationships with the financial community to our company.  I look forward to working with them as we continue to raise awareness of Kiadis within the financial markets, as well as the medical community, in both the US and Europe.”

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH